Gastrointestinal signet ring cell malignancy: current advancement and future prospects [0.03%]
胃肠道幽门螺杆菌相关恶性肿瘤的现状及未来展望
Weiping Hong,Qingjun Hu,Yuan Tan et al.
Weiping Hong et al.
Globally, gastrointestinal cancer is the most widespread neoplastic disease and the primary contributor to cancer-associated fatalities. Gastrointestinal signet ring cell carcinoma (SRCC) exhibits unique distinguishing features in several a...
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts [0.03%]
基于日本专家意见的不可手术胃肠道神经内分泌肿瘤系统治疗一线策略的最佳选择
Yoshitaka Honma,Masafumi Ikeda,Susumu Hijioka et al.
Yoshitaka Honma et al.
There are several options for systemic therapy of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), including somatostatin analogues (SSA), molecular-targeted agents, cytotoxic agents, and peptide receptor radionuclide therapy. How...
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial [0.03%]
阿帕替尼联合依托泊苷治疗广泛期小细胞肺癌的疗效：单臂Ⅱ期临床试验
Yuan Wu,Xuefeng Zhou,Weiqing Zhao et al.
Yuan Wu et al.
Background: Anlotinib plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) achieves good efficacy, but there is still room for improvement. This clinical study examined the effect...
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation [0.03%]
吉非替尼治疗EGFR L858R和A871G复合突变肺腺癌患者的有效性研究
Yujie Cui,Jinlong Liang,Xiyun Kang et al.
Yujie Cui et al.
Pulmonary enteric adenocarcinoma (PEAC) is a rare lung adenocarcinoma with morphological and immunohistochemical similarities to colorectal adenocarcinoma and intestinal differentiation. PEAC belongs to the group of non-small-cell lung carc...
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States [0.03%]
在美国进行的用于治疗晚期实体瘤患者的弗魯喹替尼一期/一二期剂量递增开放标记临床试验
Andrea Wang-Gillam,William Schelman,Stacey Ukrainskyj et al.
Andrea Wang-Gillam et al.
This open-label, phase 1/1b study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of fruquintinib in United States (U.S.) patients to confirm the recommended phase 2 dose (RP2D) established in China. Patients w...
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid [0.03%]
纳武单抗诱导的天疱疮的临床特征、治疗及结局
Miao Liu,Maoye Yuan,Wei Sun et al.
Miao Liu et al.
Background: Bullous pemphigoid (BP) is a serious and rare complication of nivolumab. This study aimed to explore the clinical characteristics of nivolumab-induced BP and provide a reference for prevention and treatment of...
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma [0.03%]
换用达雷妥尤单抗剂型对多发性骨髓瘤患者的疗效及药物浓度的影响：从静脉注射转换为皮下注射的安全性与有效性分析
Kenta Yamaoka,Kei Irie,Nobuhiro Hiramoto et al.
Kenta Yamaoka et al.
The intravenous administration (IV) of daratumumab sometimes causes an infusion reaction and needs a long infusion time. Recently, a subcutaneous formulation (SC) of daratumumab, which has fewer infusion reactions and shorter administration...
A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia [0.03%]
一种新型抗肿瘤喹诺酮化合物(R)-WAC-224对急性髓系白血病具有抑制作用
Tatsuji Mino,Hiroshi Ureshino,Taichi Ueshima et al.
Tatsuji Mino et al.
Approximately 60%-80% of patients who achieve complete remission eventually relapse after conventional chemotherapy and have poor prognoses despite the recent advances of novel anticancer agents. Continuing development of more effective nov...
A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer [0.03%]
一种新型的针对c-MET / PD-1双特异性抗体对c-MET / PD-L1阳性结直肠癌表现出强力细胞毒作用
Z Sun,C Gu,X Wang et al.
Z Sun et al.
Previously, we generated a novel bispecific antibody (BsAb) simultaneously targeting both c-MET and PD-1 (PDCD1), which can bridge T cells and c-MET positive tumor cells. However, the specific mechanisms and antitumor activities of the BsAb...
The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis [0.03%]
RET融合阳性非小细胞肺癌选择性RET抑制剂疗效和安全性的荟萃分析
Jun-Yi Ke,Shu Huang,Zhi-Tao Jing et al.
Jun-Yi Ke et al.
Rearranged during transfection (RET) fusion-positive occurs in approximately 2% of non-small cell lung cancer (NSCLC). This mutation often predicts metastasis risk and poor prognosis, and current mainstream therapies provide limited patient...